|
|
|
|
|
|
|
|
|
|
|
04.11.25 - 17:24
|
Reeves wants to talk about the budget, but she′s taken a vow of white noise | John Crace (The Guardian)
|
|
|
It must be tough overseeing Schrödinger's economy, fixing the foundations while also failing to fix themIt's this season's fashion accessory for every politician. Outside election campaigns, press conferences usually signal major set piece events or a national emergency. Now you can't move for them. Reform have had four inside a week with another one lined up for tomorrow. Even Kemi Badenoch has been at it with a bizarre outdoors show-and-tell last Thursday. Blink and you would have missed it.Tuesday was Rachel Reeves's turn. Her Lance Corporal Jones “Don't Panic! Don't Panic!” moment. Normally a chancellor takes a vow of silence in the weeks leading up to the budget. Locked away in the Treasury, head down over economic forecasts, anxious to give nothing away. Continue reading......
|
|
|
22.10.25 - 14:36
|
Schrödinger to Announce Third Quarter 2025 Financial Results on November 5 (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.
The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event.
About Schrödinger
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally....
|
|
|
|
|
|
|
18.09.25 - 13:03
|
Lazard Hires Geoffrey Porges to Healthcare Advisory Group (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Lazard announced today that Dr. Geoffrey Porges has joined the firm as Managing Director in the Healthcare Advisory Group, advising on transactions across diversified biopharmaceuticals.
“We are thrilled to welcome Geoffrey to Lazard,” said David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare. “His deep understanding of the biopharmaceutical industry's strategic and financial landscape, coupled with his ability to help companies translate scientific innovation into actionable business strategies, will empower our clients to strengthen their competitive positions, capitalize on growth opportunities, and build resilient companies in a challenging geopolitical and macroeconomic environment.”
Dr. Porges brings more than 30 years of experience in advisory, executive, and investment roles in the biopharmaceutical industry. Most recently, he served as EVP and Chief Financial Officer at Schrödinger, where he oversaw financial operations, investor r...
|
|
|
|
|
|
|
|
|
|
|
06.08.25 - 22:06
|
Schrödinger Reports Second Quarter 2025 Financial Results (Business Wire)
|
|
|
Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million
Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance
Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development
Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended June 30, 2025.
"In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven computational technologies to accelerate molecular discovery,” said Ramy Farid, Ph.D., chief executive officer of Schrödinger. “In addition to progressing several collaborative programs in our pipeline, we achieved an important milestone with the presentation of encouraging initial data for ou...
|
|
|
25.07.25 - 14:36
|
Schrödinger to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.
The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event.
About Schrödinger
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximat...
|
|
|
|
|
|
|
|
|
|
|
06.06.25 - 09:31
|
Schrödinger: Das KI-Must-have in der Medikamentenentwicklung? (Der Aktionaer)
|
|
|
Künstliche Intelligenz (KI) wird viele Branchen regelrecht disruptieren. Auch in der Medikamentenentwicklung von Morgen könnte der Einfluss der bahnbrechenden Technologie mittel- bis langfristig für neue Durchbrüche sorgen. Anleger sollten hier unbedingt das US-amerikanische Unternehmen Schrödinger auf dem Zettel haben....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
